On Dec. 16, 2020, BioNTech and Shanghai Fosun Pharmaceutical announced an agreement to supply Mainland China with an initial 100 million doses of their BNT162 mRNA-based vaccine candidate against COVID-19 in 2021, subject to regulatory approval. Initial supply will be delivered from BioNTechﾒs production facilities in Germany.